Trump’s Schedule III play

The better question is simpler and more unnerving: what happens when a President decides the machinery already sitting on the table should finally be used the way it was built to be used—and staffs the relevant agencies with people who don’t confuse delay with virtue.

According to the Washington Post, Trump has been discussing an executive order aimed at reclassifying marijuana from Schedule I to Schedule III, with HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz in the room and Speaker Mike Johnson on the phone opposing it. Reuters reported the same expectation and the market reaction, while noting the decision was not yet final.

The story here is not magic presidential power. The story is tempo, personnel, and a rescheduling docket that already exists—complete with the scientific recommendation, the proposed rule, and the procedural knots that kept it from crossing the finish line.

What an executive order can and cannot do

A President cannot personally rewrite the drug schedules by proclamation. The Controlled Substances Act does not hand the Oval Office a Sharpie and a scheduling chart. It hands the executive branch a process, and it places the legal “move the substance” act inside DOJ and the DEA, with HHS supplying the scientific and medical backbone.

What the President can do is command priorities inside the executive branch. He can set deadlines, change leadership, direct litigation posture, and tell DOJ and HHS that the rescheduling project is no longer a file that sits under a coffee mug until the next election. The Post’s reporting makes that managerial theory of power explicit: Trump can’t unilaterally reschedule marijuana, but he can direct the Justice Department to push through the rulemaking—potentially even by bypassing the ongoing administrative hearing.

That distinction matters because it turns the pundit question—“Can he?”—into the real-world one—“How fast will his agencies move, and how clean will the record be when the lawsuits start?”

The rescheduling file is already open and already thick

This did not begin as a Trump brainstorm. It began when President Biden asked for a review in October 2022. HHS conducted its scientific and medical evaluation and, in August 2023, recommended moving marijuana from Schedule I to Schedule III.

In May 2024, DOJ/DEA published a notice of proposed rulemaking to transfer marijuana to Schedule III. That is the formal start of the legal act that changes the schedule: notice-and-comment rulemaking, the kind that lives forever in the administrative record and gets dissected in court.

This is the part commentators routinely skip: the government already did the hardest, slowest work—assembling the scientific recommendation, moving it through DOJ, and publishing a proposed rule. That means Trump isn’t trying to invent a pathway. He’s trying to accelerate a pathway that already exists.

The statutory lever Biden pulled and Trump can yank harder

The Controlled Substances Act sets up a two-agency structure. DEA (through DOJ) has scheduling authority, but before DOJ can move, it must get HHS’s written scientific and medical evaluation and recommendation. The statute then makes HHS unusually powerful in one specific way: HHS’s recommendations are binding on the Attorney General “as to such scientific and medical matters.”

DOJ itself emphasized this constraint in a 2024 memo responding to questions about marijuana rescheduling, noting again that HHS’s scientific and medical determinations are binding on DOJ in the process.

In other words, the science call is already on paper, already transmitted, and already baked into the proposed rulemaking record. Trump doesn’t need to “prove” marijuana has accepted medical use from scratch. He needs his administration to finish the regulatory job that has been marinating in procedure.

Where the Biden process got bogged down

Rulemaking is where Washington goes to “act” while remaining emotionally committed to not acting.

After DEA proposed rescheduling, the agency moved into a hearing posture. A Federal Register notice set the hearing process in motion for the proposed Schedule III transfer.

Then the process hit administrative turbulence. By early 2025, credible policy and legal analysis described the hearings as postponed or cancelled pending an interlocutory appeal and related procedural issues. The Drug Enforcement and Policy Center at Ohio State’s Moritz College of Law tracks that the hearing scheduled to begin in January 2025 was postponed while an appeal was resolved.

This is the “legal limbo” the Post is talking about when it describes a White House considering bypassing the administrative hearing.

So Trump isn’t stepping into a pristine process. He’s stepping into a stalled one, and that stall creates a political opportunity: declare the delay unacceptable, then order DOJ and DEA to produce a final rule on a faster internal schedule.

Why courts sometimes stop executive branch power, and why rescheduling is a different animal

Every serious executive power story eventually meets its natural predator: the federal judge with a calendar.

When courts crush executive action, they usually do it for two reasons. The first is that the President tried to exercise power Congress never granted. Youngstown Sheet & Tube is the canonical case: Truman seized steel mills during the Korean War, and the Supreme Court held he lacked constitutional or statutory authority to do it.

The second reason is procedural: the executive branch claims it is acting under a statute, but it tries to shortcut the legally required process, or it produces a record so thin it fails basic administrative-law review. That is the kind of vulnerability that haunts immigration “big moves,” including the Obama-era DAPA litigation, where courts accepted arguments that the program likely exceeded statutory authority and ran afoul of required constraints, freezing it before it could take effect.

Trump knows this terrain because he has lived it. His original 2017 travel ban was rapidly blocked, revised, and fought through the courts until the Supreme Court ultimately upheld the third iteration in Trump v. Hawaii.

Marijuana rescheduling does not resemble Youngstown in its core authority question, because Congress delegated drug scheduling authority to the executive branch through the CSA. The Congressional Research Service summarizes the two routes clearly: Congress can schedule by statute, or the Attorney General (delegated to DEA), in conjunction with HHS, can schedule via the administrative process in the CSA.

That does not make it immune. It simply shifts the likely battlefield from “you have no authority” to “you did not follow the law’s process” and “your rule is arbitrary and capricious under the Administrative Procedure Act.” Courts reviewing agency action look for reasoned decisionmaking, not vibes. State Farm is a classic reminder that agencies must provide a rational explanation grounded in the record when they act.

That is why the Post’s “bypass the hearing” detail is both the accelerant and the hazard. Speed helps Trump politically. Sloppiness helps his challengers legally.

The Guardrails Myth, and the People Who Actually Pull the Levers

This is where the conversation stops being academic and becomes operational, because Washington has always been run less by constitutional theory than by human beings with badges, budgets, and signature blocks.

During Trump’s first administration, a comforting storyline took hold among donors, columnists, and the “I read The Federalist Papers once on a plane” set: the grownups were in charge. The President would be “managed.” Serious national-security types, conventional Republicans, and institutionalists would keep the guardrails up—protect the system from Trump’s own impulses, or at least sand down the sharp edges before they reached the rest of us. That “adults in the room” idea wasn’t a fringe whisper; it became a mainstream way of reassuring anxious elites that the state would remain on autopilot even if the cockpit was chaos.

Trump’s first term was what happened when that fantasy met a President who treats dissent as disloyalty and disloyalty as a firing offense. The result was not a calm, disciplined executive branch. It was churn. High turnover became a defining feature, and nowhere did the revolving door spin faster—or more publicly—than in the communications and press operation, which cycled through leadership at a rate that made prior administrations look monastic. Brookings tracked the rapid succession of communications directors and press secretaries; Axios, among others, documented the same “revolving door” pattern in real time.

That history matters because it explains what “personnel is policy” really means in Trump-world. The first-term model—hire people to restrain him, then punish them when they try—left behind a trail of burned reputations, abrupt departures, and cautionary tales that every ambitious appointee in Washington has been studying ever since. The institutionalists who thought their job was to manage the President discovered that, in this White House, the job description is simpler: execute the President’s priorities, on the President’s timeline, and don’t confuse your conscience with a veto.

The second-term environment has only intensified that lesson—not just through political appointments, but through the broader effort to “optimize” government itself. Trump signed orders pushing agencies toward workforce reductions and reorganizations tied to the “Department of Government Efficiency” effort associated with Elon Musk, a campaign framed as cost-cutting and anti-waste but experienced inside agencies as disruption with real institutional casualties. Government Executive reported on orders requiring agencies to plan layoffs and coordinate workforce reductions through DOGE.

And people did not merely grumble. They left. In February 2025, resignations by federal technologists connected to the former U.S. Digital Service became a national story because the departing staff described the DOGE shift as incompatible with protecting core systems and public services; the Associated Press covered the resignations and the language of the protest letter, and Politico reported the same episode as an internal revolt over how DOGE was being carried out. The Washington Post simultaneously reported sharp concerns about DOGE’s access to sensitive data and the legal and security alarms it triggered, along with litigation and judicial intervention.

In any other country, a wealthy private actor barreling through state systems, slashing capacity, and grabbing data would invite vocabulary Americans are trained to avoid saying out loud. Here we call it “efficiency” and argue about the font on the organizational chart. Either way, the practical takeaway is the same: the second-term executive branch is structured—and scarred—by the memory of what happened to people who mistook themselves for guardrails.

That brings us back to marijuana rescheduling, because this is not a policy that executes itself. If the White House decides to push Schedule III quickly, it will be done by the people sitting at the choke points.

Pam Bondi, as Attorney General, sits atop DOJ and therefore above DEA in the chain of command, and DOJ publicly documents her swearing-in. Robert F. Kennedy Jr., as HHS Secretary, controls how aggressively HHS defends and reinforces the existing scientific and medical evaluation that already undergirds the rescheduling effort. HHS documents his swearing-in. Terrance C. “Terry” Cole, as DEA Administrator, leads the agency that ultimately issues the final rule that changes the schedule; DEA documents his swearing-in. Mehmet Oz, as CMS Administrator, doesn’t decide scheduling, but he matters to the politics and downstream health-policy posture that will be used to sell and normalize the shift; his confirmation and swearing-in are documented in public reporting and official coverage.

One detail has to be stated cleanly because precision is armor in a fight like this: Sara Carter is not the sitting ONDCP Director. Her nomination was withdrawn, and contemporaneous public materials identify Jon E. Rice as the senior official performing the duties of director in an acting capacity.

None of this “guarantees” rescheduling. Courts exist. Procedure exists. Opposition exists. But it does change the internal physics. Trump’s first term trained Washington that appointees hired to “manage” him do not last. His second term has added a broader lesson: disruption is not an accident; it is a governing style. In that context, when the White House decides a stalled rulemaking must move, the people in the relevant seats are far less likely to treat delay as a virtue—and far more likely to treat it as insubordination.

How the move would unfold in the real world

Assuming Trump issues the order described in the Post and Reuters reporting, the near-term mechanics are straightforward.

The White House would frame the executive order as a directive to DOJ and HHS to complete rescheduling expeditiously. The legal work would not be done by the President’s signature; it would be done by the final rule published by DEA/DOJ.

HHS’s role would largely be to stand behind the existing scientific and medical evaluation and to ensure the record remains coherent. Because the CSA makes HHS’s scientific and medical determinations binding on DOJ “as to such scientific and medical matters,” HHS is not window dressing in this process; it is the statutory spine.

DOJ and DEA would then have to decide how to resolve the existing hearing posture and produce a final rule. The final rule is where the schedule actually changes. The administrative posture matters because it shapes the record that courts will review. The Moritz Drug Enforcement and Policy Center timeline and other legal analyses reflect that the hearing has already been postponed and the proceeding snarled by appeal.

This is why the “bypass the hearing” concept is so politically attractive: it treats the stalled hearing track as a problem to be cleared, not an altar to be worshiped. It’s also why opponents will sue. They will argue the agency failed to provide required process, ignored objections, or violated the APA. Trump’s DOJ will argue the core statutory prerequisites were satisfied—HHS delivered the scientific recommendation and DEA followed rulemaking requirements—while insisting the executive branch has discretion to manage its internal proceedings and move to final agency action.

If Trump’s team moves carefully, it can publish a final rule quickly while keeping the record defensible. If it moves recklessly, it may still publish a final rule quickly, but it could lose the first emergency motion in federal court, buying opponents months of delay and a narrative that the administration cut corners.

Why this feels inevitable, even though it is not automatic

The strongest argument that Trump can pull this off is not ideological. It is bureaucratic.

The rescheduling project already has the fundamental prerequisites: a written HHS recommendation, a published NPRM, and a process that is already deep into the administrative pipeline.

The strongest argument that Trump will try is political: this is a high-salience move that can be framed as modernizing federal policy without “legalizing marijuana,” and it can be pitched as freeing research while shifting enforcement focus toward fentanyl and other lethal drugs. That framing fits neatly inside Trump’s preferred “tough on the real poison” posture, while offering real economic and regulatory consequences for the cannabis industry.

The strongest argument that he could still get slowed down is legal: the rule has to survive judicial review. Authority is the easy part here because Congress built a lane for the executive branch. Procedure is the hard part because courts can freeze agency action when the record looks rushed, incomplete, or internally contradictory.

That is the whole story. Not whether Trump owns a magic pen. Whether the executive branch he commands can move fast, stay inside the statutory guardrails, and absorb the litigation that comes with trying to make federal marijuana policy match the country it governs.